Company Filing History:
Years Active: 2005-2014
Title: The Innovations of Arnoldus H J Herremans
Introduction
Arnoldus H J Herremans is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cannabinoid receptor compounds. With a total of seven patents to his name, Herremans has established himself as a key figure in innovative drug development.
Latest Patents
Herremans' latest patents include a group of novel 1H-imidazole derivatives. These compounds are designed to act as potent cannabinoid-CB receptor agonists, partial agonists, or antagonists. They hold promise for treating psychiatric and neurological disorders, as well as other diseases involving cannabinoid neurotransmission. The compounds are characterized by a general formula that specifies the meanings of R and R-R as detailed in the patent specification. Another significant patent involves a group of novel 4,5-dihydro-1H-pyrazole derivatives. These derivatives serve as potent cannabinoid receptor antagonists, useful for addressing diseases related to disorders of the cannabinoid system. The invention also outlines methods for preparing these compounds and pharmaceutical compositions containing them as active components.
Career Highlights
Throughout his career, Arnoldus H J Herremans has worked with prominent companies in the pharmaceutical industry, including Solvay Pharmaceuticals B.V. and Solvay Pharmaceuticals GmbH. His work has focused on the intersection of chemistry and medicine, leading to advancements in therapeutic options for patients.
Collaborations
Herremans has collaborated with notable colleagues such as Josephus H M Lange and Cornelis G Kruse. These partnerships have contributed to the development of innovative solutions in the pharmaceutical field.
Conclusion
Arnoldus H J Herremans is a distinguished inventor whose work in cannabinoid receptor compounds has the potential to transform treatment options for various disorders. His contributions to the pharmaceutical industry are noteworthy and continue to influence future innovations.